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Dear Editor, 
 
In their letter to the Editor, Klaschik et al. argue that deletion of a large portion of 
GPRC5A gene in human breast cancer cell line MDA-MB-231 has no effect on 
expression of BRCA1, does not induce apoptosis, and does not sensitize cells to 
carboplatin. They also use a large data set to demonstrate that germ-line mutations in 
GPRC5A are not more frequent in BRCA1 mutation carriers compared with the general 
population. Based on these two lines of evidence, they conclude that the role of 
GPRC5A in initiation and progression of breast cancer is of minor importance, thus 
contradicting our earlier suggestions. 
Our initial conclusion about mutual effects on gene expression between GPRC5A and 
BRCA1 was made based on siRNA-mediated knock-down in MDA-MB-231 cells as 
detected by immunofluorescence and qPCR. This effect was later independently 
reproduced in HeLa cells using siRNA- and shRNA-mediated knock-down and detected 
by Western blotting (see Fig. 1A & B). We also noticed that shRNA-mediated depletion 
of GPRC5A usually produced a milder cellular phenotype compared with siRNA-
mediated knock-down (data not shown), which could be explained by adaptations or 
phenotypic selection taking place over the course of several weeks needed to establish a 
stable cell line carrying a shRNA in contrast to a transient transfection of siRNA taking 
only a couple of days. Klaschik et al. used CRISPR/Cas9-mediated GPRC5A knock-out 
(KO) in their experiments. Although this should in theory provide a better experimental 
model entirely lacking a functional protein, it requires a very long period of cell cloning 
and selection and increases a potential negative selection if the target gene is essential 
for cell growth and viability. As a result, the GPRC5A knock-out cells generated by 
Klaschik et al. would be less likely to show some effects visible in quick siRNA-
experiments. We would also like to point out that the experimental data of Klaschik et 
al. appear to be based on a single clone of GRPC5A knock-out cell line (and three 
control clones), which may not be representative of a wider cell population. 
Although we do believe that depletion of GPRC5A indeed has a negative effect on 
BRCA1 (and vice versa), its magnitude varied between different HeLa and MDA-MB-
231 cell lines. In addition, one of our shRNAs targeting GPRC5A appeared to increase 
rather than decrease BRCA1 level (lane 2 in Fig. 1B). However, this shRNA also 
produced a number of unusual phenotypic changes that were not observed with other 
GPRC5A-targeting reagents, suggesting an off-target effect (data not shown). 
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Perturbations of GPRC5A and BRCA1 seem to involve also p53 and ATR genes (Fig. 
1A), suggesting that the relationship between GPRC5A and BRCA1 may be indirect, 
possibly mediated by p53. 
Klaschik et al. did not observe any significant differences between GPRC5A KO and 
wild-type clones when the level of PCNA was measured by Western blotting and 
concluded that GPRC5A has no effect on cell proliferation. However, a bulk PCNA 
protein level cannot reliably reveal small differences between cell populations. 
Immunocytochemical detection of a PCNA-positive cell population or the number of 
mitotic figures would be a better marker of proliferation in their case. We used an 
IncuCyte automatic imaging system (Sartorius) measuring cell confluence every 3 hours 
as a proxi for cell proliferation and found that suppression of GPRC5A inhibits cell 
proliferation at least in MDA-MB-231 (siRNA-mediated knockdown, Fig. 1C) and 
HeLa (CRISPR/Cas9-mediated knockout, Fig. 1D) cells by 10% - 15%, while 
overexpression of GPRC5A using a specific version of activating Cas9 construct seems 
to improve cell proliferation in HeLa cells (Fig. 1D). In fact, data showing a reduced 
proliferation of MCF7 and T47D breast cancer cell lines after GPRC5A depletion have 
been published earlier by others.
1
 However, we do not yet understand the mechanistic 
link between GPRC5A and cell proliferation. Klaschik et al. did not observe an increase 
in Caspase-3 in GPRC5A KO cells on a Western-blot. Neither did we observe any 
increase in a fraction of annexin V-positive HeLa cells stably expressing GPRC5A-
targeting shRNA (data not shown). However, we did see a strong increase of cleaved 
PARP, another apoptotic marker, in three cell lines (HeLa, MDA-MB-231, MCF10A) 
after depletion of GPRC5A with siRNA (Fig. 1G) indicating that apoptotic pathway has 
been activated at least to some extent. In addition, similar to MDA-MB-231 cells shown 
earlier
2
, we found a slightly reduced radiation-induced RAD51 nuclear foci formation in 
HeLa cells independently depleted for GPRC5A with 2 siRNAs, although the number of 
foci was much higher compared with depletion of BRCA1 (Fig. 1E). In our hands, 
HeLa cells stably expressing shRNA targeting GPRC5A were also slightly more 
sensitive to ionizing radiation (Fig. 1F). This result appears to contradict the carboplatin 
sensitivity data by Klaschik et al. However, they measured cell viability 48 h after 
starting carboplatin treatment, which may not be enough time to reveal small 
differences in sensitivity. We typically perform measurements 3-5 days after beginning 
a drug treatment. Cell adaptation and clonal selection during KO cell generation could 
also play a role. 
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Klaschik et al. did not observe any significant correlation between GPRC5A and BRCA1 
germline mutations in an impressive collection of several thousands of breast cancer 
samples in contrast to our earlier findings. Now we analyzed 118 additional samples 
with BRCA1 5382insC allele and found the GPRC5A c.183delG mutation present 3  
(2.5%) cases, which was still higher than in BRCA1 mutation-negative breast cancer 
patients (8/1578 0.5%; see Sokolenko et al.
2
). We agree that our data are still too small 
to support the link between GPRC5A and BRCA1-mediated breast cancer risk. We 
speculate that this over-representation of GPRC5A c.183delG variant among BRCA1 
heterozygotes could be limited to certain BRCA1 mutations (e.g., BRCA1 5382insC), 
possibly due to simultaneous persistence of two founder alleles in a given population. 
Based on their genetic data and a study by Jorissen and colleagues,
3
 Klaschik et al. 
conclude that GPRC5A is of minor significance for breast cancer. In contrast, our new 
data suggest that breast cancer is characterized by significant changes in GPRC5A 
expression level. First, a higher expression of GPRC5A in a panel of 3951 microarray 
samples publicly available in the Kaplan-Meier Plotter resource (kmplot.com)
4
 is 
associated with a significantly lower relapse-free survival (Supporting Information Fig. 
S1A). Second, we detected a significantly higher level of GPRC5A protein in malignant 
mammary tumors compared with benign cases when we stained a commercial tissue 
microarray purchased from US Biomax, Inc., using a GPRC5A antibody extensively 
characterized within the Human Protein Atlas project (Supporting Information Fig. 
S1B). Third, using this tissue microarray, we found a direct correlation between 
GPRC5A and the estrogen receptor status within all breast cancers, on the one hand, 
and between GPRC5A and a proliferation marker Ki67 within ER-positive, but not ER-
negative invasive ductal carcinomas, on the other hand (Supporting Information Fig. 
S1C and D). This correlation was even stronger at the mRNA level (Supporting 
Information Fig. S1E and F). A connection between GPRC5A and estrogen signaling is 
further supported by induction of GPRC5A protein expression in MCF7 cells treated 
with beta-estradiol (Supporting Information Fig. 1G). Taken together, these data suggest 
a role for GPRC5A in breast cancer progression possibly associated with estrogen 
receptor signaling, while its role in BRCA1-mediated breast cancer risk remains 
uncertain. 
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FIGURE LEGEND 
 
Figure 1. GPRC5A affects cell proliferation. A, Western blot showing HeLa cells 
with (+) or without (-) shRNA targeting GPRC5A 60 hours after transfection with 
siRNAs listed above and probed with antibodies against proteins listed on the left. B, 
Western blot showing effect on BRCA1 protein expression in HeLa cells expression 
different shRNAs against GPRC5A (shGPRC5A) or non-targeting control (shControl). 
C, Growth curve of MDA-MB-231 cells plated in IncuCyte imager at the same density 
48 h after a transient transfection with listed siRNAs. A total culture confluency has 
been measured automatically every 3 h. D, Growth curve of HeLa cells carrying either 
CRISPR/Cas9 construct targeting GPRC5A (KO) or an activating CRISPR/Cas9a 
construct upregulating GPRC5A level (ACT), or non-targeting CRISPR/Cas9 construct 
(Control). Cell confluence has been measured using IncuCyte imager. E, HeLa cells 
transfected with siRNAs targeting GPRC5A produce slightly fewer radiation-induced 
nuclear RAD51 foci. The assay was performed exactly as described in Sokolenko et al.
2
, 
and foci quantification and curve fitting were performed automatically. F, HeLa cells 
stably expressing shRNA targeting GPRC5A (shGPRC5A) are more sensitive to 
gamma-irradiation than control cells (shControl). Cell proliferation was measured 3 
days after irradiation using an Alamar Blue metabolic assay. Cells treated (RA+) or not 
treated (RA-) with 100 nM all-trans retinoic acid are shown. G, Western blot showing 
the effect of GPRC5A depletion (siGPRC5A) and retinoic acid treatment (atRA) on 
PARP cleavage in 3 different cell lines listed above. 
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